Navigation Links
Elsevier Welcomes New Editor-in-Chief for European Urology
Date:1/28/2013

AMSTERDAM, The Netherlands, January 28, 2013 /PRNewswire/ --

Elsevier, a world-leading provider of scientific, technical and medical information products and services, welcomes Dr. James Catto, MB ChB, PhD, FRCS (Urol), of the Academic Urology Unit, Royal Hallamshire Hospital in Sheffield (UK) as the new Editor-in-Chief of European Urology, the official journal of the European Association of Urology (EAU).

The journal has been a prestigious urological forum for over 35 years, and is currently read by more than 20,000 urologists across the globe. With an impact factor of 8.493, European Urology is now the leading scientific publication in the field of urology. Dr. Catto will replace Professor Montorsi effective January 1, 2014.

In his new role, Dr. Catto aims to strengthen the journal's success and envisions European Urology as a high quality and high impact journal which is supported by a robust multimedia platform and a user-friendly interface.

"We will expand into social media platforms and create a more interactive user experience. I will try to broaden our appeal to other professionals, but at our core we will remain a high quality urological journal that serves and highly values its readers and authors," explained Dr. Catto. "European Urology greatly contributes to the mission of the EAU - improving the care for patients with urological disease - and this is a tremendous motivation for me. As Editor-in-Chief, I will be able to focus the minds of our readership upon crucial clinical issues, whilst driving forward change and innovation. I aim to keep urologists at the forefront of clinical developments and make them key to high quality patient care."

"I am thankful to work with the EAU and also very grateful for its support and input over the last years. I look forward to working with the newly appointed Editor-in-Chief, Dr. James Catto and his editorial team. The management and cure of for instance prostate cancer as well as the advanced search for the basic mechanisms of urologic diseases are major and global challenges of the 21st century. Elsevier is confident to make European Urology a continuing and growing success for authors, readers and for the EAU," commented Koos Admiraal MD, Executive Publisher for Elsevier.

About European Urology
European Urology, the official journal of the EAU, has been a prestigious urological forum for over 35 years, and is currently read by more than 20,000 urologists across the globe. With an impact factor of 8.493, the journal is now the leading scientific publication in the field of urology. For more information, go to: http://www.europeanurology.com

About the European Association of Urology
The European Association of Urology (EAU) is a non-profit organisation which supports medical professionals working in the field of urology through many of its scientific, professional, educational and awareness-building initiatives. Through its work the EAU aims to raise the level of urological care in Europe. For more information about the EAU, go to: http://www.uroweb.org

About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact

Carolien van der Zanden
Elsevier
+31-20-485-3346
c.zanden@elsevier.com



'/>"/>
SOURCE Elsevier
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Peter C. Neligan, Author of 3rd Edition of Elseviers Plastic Surgery Text, Available for Comment on the Contributions of Dr. Joseph Murray
2. Elsevier and the Dutch Fulbright Center Start Collaboration to Support Early Career Researchers in the Netherlands
3. Elsevier Offers Entire Collection of Journals and Books to Innovators in Developing Countries Through the Access to Research for Development and Innovation (ARDI) Program
4. Elsevier Acquires ExitCare, Provider of Patient Education Solutions
5. Elsevier Collaborates With Infocomm Development Authority of Singapore and Top Academic Institutions to Bring CodeForScience to Singapore
6. Elsevier / Gold Standard Announces New Drug Class Overviews for Clinical Pharmacology
7. Elsevier / MEDai Names Dr. Peter Edelstein as Chief Medical Officer and Dr. Gerald Osband as Director of Product Strategy
8. Elsevier Launches New Journal: Performance Enhancement & Health
9. Elsevier Expands Access to Digital Offerings Through Collaboration with Follett
10. Northwestern University Joins VIVO Network with Elseviers SciVal Experts
11. Society of Biological Psychiatry and Elsevier Renew Publishing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
(Date:2/16/2017)... and NEW YORK , Feb. 16, ... completion of their $7M Series B financing, adding an ... the $3.5M led by Mesa Verde Venture Partners and ... resources will be directed towards further accelerating commercial adoption ... comprehensive genomic profiling test and expanding the Paradigm cancer ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. ... Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung ... Klasse führenden Plattform für die Entdeckung monoklonaler Antikörper. ... ihr neuartiges chimäres Gensegmentdesign aus, das Janssen ... humanen Antikörpern bietet und das für die schelle ...
(Date:2/15/2017)... -- Windtree Therapeutics, Inc. (Nasdaq: WINT ), ... therapies for respiratory diseases, will host a conference call ... EST on Thursday, February 16, 2017 to provide updates ... announced closing of a $10.5 million private offering and ... in the live call and take part in the ...
Breaking Biology Technology:
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to its ... meaningful advances worldwide, The Japan Prize Foundation today ... who have pushed the envelope in their respective ... Communication. Three scientists are being recognized with the ... that not only contribute to the advancement of ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
Breaking Biology News(10 mins):